You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0323 The endothelial-to-mesenchymal transition (ENDOMT) in scleroderma can be prevented by the use of dual endothelin receptor antagonists bosentan and macitentan

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
SAT0323 The endothelial-to-mesenchymal transition (ENDOMT) in scleroderma can be prevented by the use of dual endothelin receptor antagonists bosentan and macitentan
Free

 

Online download statistics by month:

Online download statistics by month: July 2017 to March 2024

AbstractFullPdf
Jul 20171000
Aug 2017800
Sep 20171600
Oct 20171804
Nov 2017400
Dec 20171000
Jan 20182205
Feb 20183003
Mar 2018800
Apr 20181001
May 2018800
Jun 2018800
Jul 20181600
Aug 2018400
Sep 2018401
Oct 2018600
Nov 20181401
Dec 20181001
Jan 2019600
Feb 20191605
Mar 2019603
Apr 2019805
May 2019802
Jun 2019401
Jul 20191202
Aug 2019402
Sep 2019401
Oct 20191802
Nov 2019801
Dec 2019401
Jan 2020801
Feb 2020202
Mar 2020802
Apr 2020201
May 2020001
Jun 2020601
Jul 20201101
Aug 2020202
Sep 20201201
Oct 2020200
Nov 2020400
Dec 2020403
Jan 2021600
Feb 2021402
Apr 2021302
May 2021008
Jun 2021002
Jul 2021102
Aug 2021004
Sep 2021002
Oct 20213013
Nov 20214014
Dec 2021404
Jan 2022201
Feb 2022500
Mar 2022701
Apr 2022202
May 20221605
Jun 20221602
Jul 2022801
Aug 2022802
Sep 20221107
Oct 2022604
Nov 2022201
Dec 2022400
Jan 2023402
Feb 2023601
Mar 20231600
May 2023003
Jun 2023301
Jul 2023405
Aug 2023002
Oct 2023501
Nov 2023201
Dec 20231400
Jan 20241001
Feb 2024402
Mar 20246023
Total5510177